There are no plans to classify surgical fires in operating theatres as Never Events.<\/p>
Never Events are defined as serious incidents that are wholly preventable because guidance or safety recommendations that provide strong systemic protective barriers are available at a national level and should have been implemented by all healthcare providers.<\/p>
Strong systemic protective barriers are defined as barriers that must be successful, reliable and comprehensive safeguards or remedies \u2013 such as a connector that stops a medicine being given by the wrong route or a window restrictor which prevents a window being opened wide enough for a patient to get through.<\/p>
There is currently no national guidance or safety recommendations that provides such safeguards to prevent surgical fires in operating theatres. These types of incidents cannot therefore be defined as a Never Event.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1481", "label" : {"_value" : "Biography information for Ms Nadine Dorries"} } , "answeringMemberConstituency" : {"_value" : "Mid Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Ms Nadine Dorries"} , "dateOfAnswer" : {"_value" : "2020-11-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-11-17T15:33:59.51Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-11-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Operating Theatres: Fire Prevention"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department plans to classify surgical fires in operating theatres as never events.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "110129"} , {"_about" : "http://data.parliament.uk/resources/1247718", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1247718/answer", "answerText" : {"_value" : "
There is broad agreement between international regulators on both the safety and the efficacy criteria that would be required for approval and authorisation of a COVID-19 vaccine. These criteria will apply to all COVID-19 vaccine candidates, irrespective of whether they receive funding from the United Kingdom Government.<\/p>
The Medicines and Healthcare products Regulatory Agency (MHRA) will perform the assessment of the quality, safety and efficacy data submitted by developers of COVID-19 vaccines and will seek the advice of its independent expert advisors on the Commission on Human Medicines.<\/p>
No approval will be given for any COVID-19 vaccine without robust evidence of efficacy and safety. The MHRA has teams of assessors available to review the submissions.<\/p>
To expedite the review of COVID-19 vaccine applications, developers of COVID-19 vaccines can submit their Marketing Authorisation Applications in the form of a rolling submissions and do not need to wait to have a complete data package before submission.<\/p>
The time taken for MHRA\u2019s review will depend on what data will be submitted and when.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2020-11-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "110170"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-11-30T12:04:29.557Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-11-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the covid-19 vaccine candidates for which the Government has provided funding, what the efficacy criteria are for each of those vaccine candidate trials; to what extent each of those efficacy criteria are required to be met in order that those vaccine candidate trials can be deemed by the Government to have achieved satisfactory outcomes; and by (a) what methods and (b) what number of people (i) in which locations and (ii) over what time periods those assessments on whether those safety criteria have been met are being made.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4446", "label" : {"_value" : "Biography information for Mr Marcus Fysh"} } , "tablingMemberConstituency" : {"_value" : "Yeovil"} , "tablingMemberPrinted" : [{"_value" : "Mr Marcus Fysh"} ], "uin" : "110169"} , {"_about" : "http://data.parliament.uk/resources/1247719", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1247719/answer", "answerText" : {"_value" : "
There is broad agreement between international regulators on both the safety and the efficacy criteria that would be required for approval and authorisation of a COVID-19 vaccine. These criteria will apply to all COVID-19 vaccine candidates, irrespective of whether they receive funding from the United Kingdom Government.<\/p>
The Medicines and Healthcare products Regulatory Agency (MHRA) will perform the assessment of the quality, safety and efficacy data submitted by developers of COVID-19 vaccines and will seek the advice of its independent expert advisors on the Commission on Human Medicines.<\/p>
No approval will be given for any COVID-19 vaccine without robust evidence of efficacy and safety. The MHRA has teams of assessors available to review the submissions.<\/p>
To expedite the review of COVID-19 vaccine applications, developers of COVID-19 vaccines can submit their Marketing Authorisation Applications in the form of a rolling submissions and do not need to wait to have a complete data package before submission.<\/p>
The time taken for MHRA\u2019s review will depend on what data will be submitted and when.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2020-11-30", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "110169"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-11-30T12:04:29.617Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-11-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the covid-19 vaccine candidates for which the Government has provided funding, what the safety criteria are for each of those vaccine candidate trials; to what extent each of those safety criteria are required to be met in order that those vaccine candidate trials can be deemed by the Government to have achieved satisfactory outcomes; and by (a) what methods and (b) what number of people (i) in which locations and (ii) over what time periods those assessments on whether those safety criteria have been met are being made.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4446", "label" : {"_value" : "Biography information for Mr Marcus Fysh"} } , "tablingMemberConstituency" : {"_value" : "Yeovil"} , "tablingMemberPrinted" : [{"_value" : "Mr Marcus Fysh"} ], "uin" : "110170"} , {"_about" : "http://data.parliament.uk/resources/1247720", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1247720/answer", "answerText" : {"_value" : "
In terms of the six supply agreements that have and are being negotiated, these cannot be provided at this time due to commercial sensitivity. We are currently also unable to provide information on funding allocated to each potential vaccine for marketing, manufacturing, distribution and administration, as they have not yet been finalised.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2020-11-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-11-18T12:59:55.22Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-11-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the covid-19 vaccine candidates for which the Government has provided funding, how much funding from the public purse has been allocated to the process of preparing each of those potential vaccines for (a) marketing, (b) manufacturing, (c) distribution and (d) administration.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4446", "label" : {"_value" : "Biography information for Mr Marcus Fysh"} } , "tablingMemberConstituency" : {"_value" : "Yeovil"} , "tablingMemberPrinted" : [{"_value" : "Mr Marcus Fysh"} ], "uin" : "110171"} , {"_about" : "http://data.parliament.uk/resources/1247723", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1247723/answer", "answerText" : {"_value" : "
A COVID-19 vaccine will only be deployed once it has been proven to be safe and effective through robust clinical trials and approved for use by the appropriate licensing authority. There are numerous potential vaccine candidates in development, which the United Kingdom will have access to. Once a vaccine is ready, it will be deployed to those most at risk, and then rolled out more widely. Regular testing of virus samples will be undertaken to assess any changes in the virus that may impact on vaccine effectiveness. Safe and effective vaccines rolled out to the population will form part of our overall recovery effort from the impact of this global pandemic.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2020-11-18", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-11-18T12:53:10.76Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-11-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment the Government has made of the potential effect of the (a) development and (b) authorisation of a covid-19 vaccine that doesn't prevent (i) transmission and (ii) fatalities on public confidence in (A) the Government response to covid-19, (B) public health programmes and (C) economic growth.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4446", "label" : {"_value" : "Biography information for Mr Marcus Fysh"} } , "tablingMemberConstituency" : {"_value" : "Yeovil"} , "tablingMemberPrinted" : [{"_value" : "Mr Marcus Fysh"} ], "uin" : "110174"} , {"_about" : "http://data.parliament.uk/resources/1247734", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1247734/answer", "answerText" : {"_value" : "
We will continue to review the evidence available to us through the Scientific Advisory Group for Emergencies, the Office for National Statistics and other sources and we continue to be guided by the science on our approach.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4527", "label" : {"_value" : "Biography information for Helen Whately"} } , "answeringMemberConstituency" : {"_value" : "Faversham and Mid Kent"} , "answeringMemberPrinted" : {"_value" : "Helen Whately"} , "dateOfAnswer" : {"_value" : "2021-02-05", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-02-05T10:46:19.597Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-11-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Research"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to assess the effect of new research into the range and frequency of covid-19 symptoms on the adequacy of his guidance on the main symptoms of covid-19 which are used to recommend that individuals book a test for the virus; and how often that assessment takes place.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4603", "label" : {"_value" : "Biography information for Preet Kaur Gill"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Edgbaston"} , "tablingMemberPrinted" : [{"_value" : "Preet Kaur Gill"} ], "uin" : "110215"} , {"_about" : "http://data.parliament.uk/resources/1247742", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1247742/answer", "answerText" : {"_value" : "
The Government\u2019s response to the pandemic is guided by the science. Data and scientific advice informing the fight against COVID-19 are published on GOV.UK and specific relevant findings are shared in presentations accompanying significant policy announcements.<\/p>
Unfortunately, we know that the virus spreads readily in indoor environments where members of different households and/or support bubbles spend time together. These restrictions do not single out restaurants, pubs or gyms but apply to a wide range of settings where the risk of transmission is high.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1481", "label" : {"_value" : "Biography information for Ms Nadine Dorries"} } , "answeringMemberConstituency" : {"_value" : "Mid Bedfordshire"} , "answeringMemberPrinted" : {"_value" : "Ms Nadine Dorries"} , "dateOfAnswer" : {"_value" : "2020-11-10", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "110271"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-11-10T21:32:59.277Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-11-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Gyms"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the evidential basis is for the decision of 31 October 2020 to close covid-19 secure gyms and sports facilities.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"} } , "tablingMemberConstituency" : {"_value" : "York Central"} , "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"} ], "uin" : "110180"} , {"_about" : "http://data.parliament.uk/resources/1247743", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1247743/answer", "answerText" : {"_value" : "
The health, safety and wellbeing of patients, communities, individuals and teams remain our absolute priority.<\/p>
NHS England and NHS Improvement\u2019s guidance \u2018Visiting healthcare inpatient settings during the COVID-19 pandemic\u2019 has consistently been that there should be reasonable adjustments to allow certain groups of people, including people with dementia, to have a family member or friend visit them if not being present would cause the patient to be distressed. This applies to all inpatient settings.<\/p>
<\/p>
In addition, to support the provision of person-centred care for older people, including those with dementia, local National Health Service trusts provide hospital passport templates that can be completed before attending hospital as an inpatient or outpatient. The hospital passport outlines, from the patient's perspective, what they would like staff to know about them and their care to help personalise their admission.<\/p>
<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"} } , "answeringMemberConstituency" : {"_value" : "Charnwood"} , "answeringMemberPrinted" : {"_value" : "Edward Argar"} , "dateOfAnswer" : {"_value" : "2020-11-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2020-11-27T21:39:57.37Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2020-11-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Dementia: Coronavirus"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of enabling a family carer to support a relative with dementia in hospital during the covid-19 outbreak.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4523", "label" : {"_value" : "Biography information for Catherine West"} } , "tablingMemberConstituency" : {"_value" : "Hornsey and Wood Green"} , "tablingMemberPrinted" : [{"_value" : "Catherine West"} ], "uin" : "110206"} , {"_about" : "http://data.parliament.uk/resources/1247747", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1247747/answer", "answerText" : {"_value" : "
Estimates of the number of children who suffer from \u2018undernutrition\u2019 is not available.<\/p>
The National Child Measurement Programme (NCMP) reports the number of children who are underweight in England. NCMP data for 2019/20 shows that the number of underweight children in England aged four to five years old is 3,771 out of 399,470 measured (0.9%) and the number of children aged 10-11 years old is 6,969 out of 491,138 measured (1.4%). This is stable compared with previous years and is below the 2% level expected in a healthy population. This data is available at the following link:<\/p>